GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Price-to-Funds-From-Operations

Sensorion (XPAR:ALSEN) Price-to-Funds-From-Operations : (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Sensorion (XPAR:ALSEN) Business Description

Industry
Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat and prevent hearing loss. The company's product is in phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.